How do you decide whether to hold acalabrutinib or zanubrutinib in patients with indolent B-cell lymphoma/leukemias in a perioperative/periprocedural setting?  

All 3 BTKis have on their FDA label "consider the benefit-risk of withholding for 3-7 days pre and post surgery depending upon the type of surgery and the risk of bleeding". Is the risk sufficiently lower with acala/zanu? Which patients do you worry about a withdrawal syndrome upon holding?